2012
DOI: 10.1111/j.1747-4949.2011.00750.x
|View full text |Cite
|
Sign up to set email alerts
|

Treatment with tPA Predicts Better Outcome Even if MCA Occlusion Persists

Abstract: Although the prognosis of patients with persisting middle cerebral artery occlusion after tissue plasminogen activator administration is known to be poor, patients do better if treated with tissue plasminogen activator vs. those who could not be treated - mainly for late presentation. This may be due to sufficient small vascular territory recanalization despite persistence of large artery occlusion after tissue plasminogen activator treatment.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
9
0

Year Published

2013
2013
2017
2017

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 15 publications
(9 citation statements)
references
References 31 publications
(33 reference statements)
0
9
0
Order By: Relevance
“…9 Moreover, early alteplase treatment was also shown to predict better outcome despite persistence of large artery occlusion. 37 Our results provide mechanistic insights that could explain these clinical data. Indeed, unlike thrombo-embolic models, the monofilament model of tMCAO mimicks such clinical situations in which the causal occlusion and proximal recanalization are not affected by intravenous thrombolytic treatment.…”
Section: Strokementioning
confidence: 93%
“…9 Moreover, early alteplase treatment was also shown to predict better outcome despite persistence of large artery occlusion. 37 Our results provide mechanistic insights that could explain these clinical data. Indeed, unlike thrombo-embolic models, the monofilament model of tMCAO mimicks such clinical situations in which the causal occlusion and proximal recanalization are not affected by intravenous thrombolytic treatment.…”
Section: Strokementioning
confidence: 93%
“…The beneficial effect of recanalization by r-tPA is undisputed; however, experimental stroke studies have also reported neurotoxic effects of r-tPA [14, 15]. It was previously reported that r-tPA leads to degranulation of neutrophils, thus increasing NE and MPO in serum [16], and that r-tPA reduces stroke lesion size or outcomes independent of successful recanalization [17, 18]. Potential off-target effects of r-tPA on innate bacterial defence mechanisms of granulocytes and monocytes have not yet been studied; they could, however, be relevant for patient outcomes.…”
Section: Introductionmentioning
confidence: 99%
“…In more recent case reports, tissue plasminogen activator (tPA), a potent fibrinolytic agent, has shown promise in ameliorating cast burden in plastic bronchitis of non-SM causes (7-10), but only anecdotally. tPA is currently used as firstline therapy in several clot-associated diseases, such as stroke (35,36) and myocardial infarction (37), and can improve survival with these life-threatening entities. In regard to plastic bronchitis, no placebo-controlled clinical trials have been done to evaluate the effects of tPA.…”
Section: Clinical Relevancementioning
confidence: 99%